Relationship between sepsis and 4G/5G polymorphism within the promoter region of plasminogen activator inhibitor-1 gene

National Medical Journal of China

Volumn 85, Issue 34, 2005, Pages 2404-2407

  Zhan, Zhi Ya ^a   Wang, Hong Wei ^b   Chen, Da Fang ^b   Cheng, Bao Li ^b   Wang, Hai Hong ^b   Fang, Xiang Ming ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NONE

Author keywords

Plasminogen activator inhibitor 1; Polymorphism; Sepsis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION MAPPING; RISK FACTOR; SCORING SYSTEM; SEPSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ALLELES; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; SEPSIS;

EID: 24744471479     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. American college of chest physicians/society of critical care medicine consensus conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med, 1992,20:864.
2. Qiu HB, Du B, Liu DW, et al. Clinical study of systemic inflammatory response syndrome and multiple organ dysfunction syndrome in critically patients. Chin J Surg, 1997,35:402-405.
3. Weigand MA, Horner C, Bardenheuer HJ, et al. The systemic inflammatory response syndrome. Best Pract Res Clin Anaesthesiol, 2004,18:455-475.
4. Menges T, Hermans PW, Little SG, et al. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet, 2001,357:1096-1097.
5. Haralambous E, Hibberd ML, Hermans PW, et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med, 2003, 31:2788-2793.
6. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet, 1999,354:556-560.
7. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003,31:1250-1256.
8. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med, 2004,30:1032-1040.
9. Chu XM, He BX. The plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and metabolischens syndrom. Chin J Cardiol, 2004,32:184-186.
10. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 Gene Locus 4G/5G Polymorphism is associated with a family history of coronary artery disease. Arterioscler, Thromb Vasc Biol, 1998,18: 152-156.
11. Zhai YL, Fu Y, Wang XD, et al. Relation between plasminogen activator inhibitor-1 and the PAI-1 gene locus 4G/5G polymorphism and their effect on the incidence of coronary heart disease. Clinical Focus, 2003,18:246-248.
12. Fu L, Kong YH, Li J, et al. The correlation between 4G/5G polymorphism located in the promoter region of PAI-1 gene and thrombotic disease. Chin J Cardiol, 2001,29:144-147.
13. Kang L, Li XY, Li JS, et al. Relationship between 4G/5G genetic polymorphism of the plasminogen activior inhibitor-1 (PAI-1) gene and peripheral arterial occlusive disease. Chin J Geriatr Cardiovasc Cerebrovasc, 2003,5:92-95.
14. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal septic shock. Lancet, 1999,354:561-563.
15. Shifman S, Kuypers J, Kokoris M, et al. Linkage disequilibrium patterns of the human genome across populations. Hum Mol Genet, 2003,12:771-776.